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background: Systolic heart failure (HF) is a progressive medical condition requiring long-term care. Numerous medications and medical devices 
are available for the treatment of systolic HF. This study evaluated the current treatment patterns of systolic HF in the US.
Methods: This is a retrospective, observational study using the large, nationally representative MarketScan Commercial and Medicare 
Supplemental Databases (1/1/2008-1/31/2013). Patients ≥18 years old with a diagnosis for systolic HF (ICD-9-CM=428.2x or 428.4x) were 
included. All patients had 12-month data prior to index date (i.e., the first systolic HF diagnosis date) and were followed from index date until the 
earliest of inpatient death or end of data. Patient demographic characteristics, use of HF medical devices such as cardiac resynchronization therapy 
(CRT) and implantable cardioverter defibrillator (ICD), and use of HF medications were summarized descriptively. Persistence was assessed by 
whether a patient experienced a gap of ≥60 days in treatment. Both persistence and medication possession ratio (MPR) were estimated for all HF 
medication combined as well as for beta-blocker separately.
results:  A total of 99,677 patients met the study criteria, with a mean age of 70.1 (SD 14.5), 59.7% male, 61.9% covered by Medicare, a mean 
of 588 (SD 472) days of follow up, and a mean Charlson Comorbidity Index of 2.0 (SD 2.1). During the follow up period, 5.7% of them received CRT, 
12.5% received ICD, and 87.1% received any HF medication: 66.6% received angiotensin-converting enzyme inhibitor (ACE) or angiotensin receptor 
blocker (ARB), 74.5% beta blocker (BB), 20.5% aldosterone antagonist, 65.1% diuretic, and 20.8% combination of BB and ACE/ARB. Among patients 
who received HF medications, 17.7% were not persistent and 28.7% had MPR<80%; among patients who received beta-blocker, 34.9% were not 
persistent on beta-blocker and 51.9% had MPR<80%.
conclusion: In spite of multiple treatment options, in US real world practice systolic HF treatment still needs improvement. The persistence to HF 
medications, especially to beta-blockers is not optimal. Future studies are needed to understand the reasons for the suboptimal persistence.
